Absolutely nothing in here shows any proof this actually works except for the marketing. Check out the bolded in pink statement below.
Moleac's Flagship Product NeuroAiD Named Asia Pacific Neurological Disorders New Product Innovation of the Year At the Frost & Sullivan Best Practices Awards
SINGAPORE, Oct. 13, 2016 /PRNewswire/ -- NeuroAiDTM has been named New Product Innovation of the Year
by Frost & Sullivan. This award recognizes healthcare products that
are bringing innovative solutions for neurological disorders by pushing
the boundaries of the usual practices. This award also acknowledges
Moleac for its effort and continuous investment in NeuroAiDTM's Research and Development. Mr. David Picard, CEO of Moleac, received the 2016 Frost & Sullivan Asia Pacific New Product Innovation Award at the awards ceremony held this evening at Conrad Singapore. The ceremony was attended by leaders from the healthcare sector.
Frost & Sullivan followed a rigorous measurement-based methodology to select NeuroAiDTM
as the recipient. Its independent panel of judges included senior
members across various offices at Frost & Sullivan. The judging
panel looked at market performance indicators, including revenue growth,
market share, availabilities, geographical expansion and marketing
strategies.
Dr. M. Shaillender, Industry Analyst, Healthcare Practice - Asia Pacific at Frost & Sullivan,
said, "Stroke rehabilitation is an underserved segment in the
pharmaceutical industry. Moleac aims to address the existing gaps in
stroke therapy with an unconventional approach similar to 'reverse innovation.' NeuroAiDTM is a product originating from Traditional Chinese Medicine
that has demonstrated excellent attributes in post-stroke recovery,
however, without any scientific and clinical evidence. Moleac's team was
instrumental in identifying and decoding the underlying neuromodulatory
properties to translate it into a therapeutic drug supported by
clinical evidence for neurological disorders."
He further adds, "As one of the first therapies of its kind, NeuroAiDTM
is today accepted as an innovative treatment for post-stroke recovery.
It is approved and marketed in over 35 countries as a supplement for
stroke rehabilitation. Executing well in its vision, Moleac is on a
trajectory to expand the horizons of NeuroAiDTM into a mainstream therapeutic drug for neurological disorders."
David Picard, CEO of Moleac, said, "I am delighted to receive this award from Frost & Sullivan while we are celebrating the 10 years' anniversary of NeuroAiDTM. Having launched NeuroAiDTM in 2006, we have been focusing our efforts on making NeuroAiDTM available to stroke sufferers around the world. NeuroAiDTM
is the first medicine to support stroke recovery, and this is a huge
unserved need for millions of suffers. In 2016, over 20,000 patients
benefited from NeuroAiDTM worldwide and we aim at making NeuroAiDTM available to more patients in the coming years."
He continued to add, "I would like to thank all those who have contributed to NeuroAiDTM's
development over the past 10 years. This includes our academic
partners, who have shown interest in our approach enabling its clinical
development, our investors who have trusted us, and of course my
colleagues who have made this venture a success. Without their support,
NeuroAiDTM would not be where it is today. We keep investing
in Research with several on-going clinical studies to provide
first-class evidences of NeuroAiDTM's benefits in other unserved neurological disorders."
NeuroAiDTM is a
natural medicine originating from Traditional Chinese Medicine. In
addition to its excellent safety profile, clinical trials have shown
that patients taking NeuroAiDTM for 3 months have higher
chances to reach functional recovery, with prolonged benefits over the
long-term as published in Cerebrovascular Diseases (April 2015). About 3,000 subjects
have been included in clinical trials and Moleac is currently
supporting additional international clinical trials to demonstrate the
potential of NeuroAiDTM in other neurological disorders.
About Moleac: Moleac is a Singapore-based biopharmaceutical company that dedicates itself to finding and developing new medicines for the unmet needs of patients worldwide.
About NeuroAiDTM: NeuroAiDTM is a post-stroke recovery treatment to help stroke survivors achieve a
faster and better recovery. Moleac also markets NeuroAiD II, a
simplified formula. Both products are shown to be equivalent in
pharmacology. It currently reaches out to patients in over 35 countries.
Contact details:
SOURCE Moleac Pte Ltd
No comments:
Post a Comment